Price Chart

Profile

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
URL https://www.aligos.com
Investor Relations URL https://investor.aligos.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 08, 2024 (est.)
Last Earnings Release Nov. 02, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
URL https://www.aligos.com
Investor Relations URL https://investor.aligos.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 08, 2024 (est.)
Last Earnings Release Nov. 02, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A